NL-OMON45234招募中不适用
Secondary Prevention of Morbus Asherman Evaluation of endometrium stimulation with estrogen gestagen post hysteroscopic adhesiolysis - SePA (Secundary Prevention of morbus Asherman)
Spaarne Ziekenhuis0 个研究点目标入组 110 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •Consented patients with M. Asherman who had a successful hysteroscopic adhesiolysis, defined as a restore of the normal uterine cavity, are eligible for inclusion. Patients with M. Asherman should be defined as patients with any diminishing of blood flow (secondary amenorrhoea or secondary hypomenorrhoe) after trauma to the uterine cavity due to pregnancy related surgical procedure with the presence of intrauterine adhesions with a previous history of normal menstrual bloodflow.
排除标准
- •- - Patients with a suspected M. Asherman due to tuberculosis or schitsosomiasis.
- •- Patients with an uncorrected anovulation, amenorrhoe or oligomenorrhoe previous to the M. Asherman syndrome
- •- Patients with suspected M. Asherman due to hysteroscopic surgery with the use of electrocoagulation (used in fibroid or polyp surgery)
- •- Patients with congenital uterine anomalies
- •- Patients with contraindications for a surgical adhesiolysis
- •- Patients who do not master the Dutch or English language.
- •- Patients who are younger than 18 years of age or mentally incompetent.
- •- Patients with contraindications for estrogen and or gestagen
- •-Patients who use hormonal suppletion
研究者
相似试验
已完成
不适用
Evaluation of endometrium stimulation with estrogen gestagen post hysteroscopic adhesiolysis and long term outcomesAsherman SyndromeNL-OMON24510o sponsor110
尚未招募
不适用
TePA-study (Tertiary Prevention of morbus Asherman-study);Evaluation of placement of hyaluronic acid (hyalobarier ® Gel Endo) and placement of a intrauterine device without cu or hormones to maintain separation of the cavity and mechanically to prevent spontaneous recurrence of adhesions.<br>Asherman10046828NL-OMON43266Spaarne Ziekenhuis110
招募中
4 期
A sub-analysis study of the prevention of atherosclerosis by SGLT2 inhibitor (a multicenter, randomized controlled study: PROTECT)Type2 diabetesJPRN-jRCT1071220089ode Koichi482
未知
不适用
Atorva-af prevention studyischemic heart diseaseJPRN-UMIN000002371Showa University School of Medicine Thoracic and cardiovascular surgery180
进行中(未招募)
1 期
Estudio ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events, aspirina para reducir el riesgo de accidentes vasculares iniciales) – Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico y de grupos paralelos para evaluar la eficacia (reducción de los acontecimientos de enfermedad cardiovascular) y la seguridad de 100 mg ácido de acetilsalicílico con recubrimiento entérico en pacientes con riesgo moderado de sufrir enfermedad cardiovascular. - ARRIVEEUCTR2006-003622-29-ESBayer HealhCare AG12,000
